Zobrazeno 1 - 10
of 1 570
pro vyhledávání: '"mCRPC"'
Autor:
Amir Karimzadeh, Charlotte-Sophie Hecker, Matthias M. Heck, Robert Tauber, Calogero D’Alessandria, Wolfgang A. Weber, Matthias Eiber, Isabel Rauscher
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Background The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high
Externí odkaz:
https://doaj.org/article/31e329c31e0949a1906aa3f3aad0cf6d
Autor:
David Ventura, Philipp Rassek, Philipp Schindler, Burak Han Akkurt, Linus Bredensteiner, Martin Bögemann, Katrin Schlack, Robert Seifert, Michael Schäfers, Wolfgang Roll, Kambiz Rahbar
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is an essential tool for patient selection before radioligand therapy (RLT). Interim-staging with PSMA-PET during RLT allows for therapy monitoring. Howeve
Externí odkaz:
https://doaj.org/article/df3f1ee603084bb3b65b7c49acbc1e64
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5080-5087 (2024)
Background: The management of advanced prostate cancer continues to evolve rapidly, particularly with the earlier use of survival-prolonging therapies in metastatic castration-sensitive prostate cancer (mCSPC). Though approved prior to the use of int
Externí odkaz:
https://doaj.org/article/08717dd41a884243aebf6bff49914062
Autor:
Sijin Chen, Dewen Zhong, Chenbo Yu, Desheng Cai, Qichen Wei, Minggen Yang, Tao Li, Qingguo Zhu, Liefu Ye, Yongbao Wei, Jinfeng Wu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-6 (2024)
Abstract Although overall survival data are still premature, the PROpel study found radiological progression-free survival (PFS) benefits of abiraterone and olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). However, f
Externí odkaz:
https://doaj.org/article/5ca27f5ab8044e2fb1dc37c979b5226b
Autor:
Dilara Akhoundova, Stefanie Fischer, Joanna Triscott, Marika Lehner, Phillip Thienger, Sina Maletti, Muriel Jacquet, Dinda S.H. Lubis, Lukas Bubendorf, Wolfram Jochum, Mark A. Rubin
Publikováno v:
Diagnostic Pathology, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) genomic alterations are rare in prostate cancer (PCa). Gain-of-function mutations lead to overexpression of β-catenin, with consequent hyperactivation of the Wnt/β-catenin s
Externí odkaz:
https://doaj.org/article/ab8d7da124964dd89f2c5fdc280d36be
Autor:
I‐Hung Shao, Hsiang‐Shen Wang, Chin‐Hsuan Hsieh, Tsung‐Lin Lee, Ying‐Hsu Chang, Liang‐Kang Huang, Yuan‐Cheng Chu, Hung‐Chen Kan, Po‐Hung Lin, Kai‐Jie Yu, Chun‐Te Wu, Cheng‐Keng Chuang, See‐Tong Pang
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
ABSTRACT Background This study aimed to identify the clinical predictors for the response of patients with mCRPC to ARATs. Materials and Methods We retrospectively collected data on consecutive patients who were diagnosed with mCRPC and underwent ARA
Externí odkaz:
https://doaj.org/article/2e7066fa5e1b493097b1b7e05e3df66d
Autor:
Florian Rosar, Caroline Burgard, Scott David, Robert J. Marlowe, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer-Schuler, Samer Ezziddin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have “mismatch” lesions with pronounced 18-fluorodeoxyglucose ([18F]FDG) bu
Externí odkaz:
https://doaj.org/article/f9053057e4e4460dbb99f656e62bc2b4
Autor:
Narjess Ayati, Lachlan McIntosh, James Buteau, Ramin Alipour, Michal Pudis, Nicholas Daw, Price Jackson, Michael S. Hofman
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background PSMA PET/CT is a predictive and prognostic biomarker for determining response to [177Lu]Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer (mCRPC). Thresholds defined to date may not be generalizable to n
Externí odkaz:
https://doaj.org/article/b04bf9cbe61641e8b0c83eb5935c6d9f
Autor:
Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1400-1415 (2024)
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistan
Externí odkaz:
https://doaj.org/article/64b195e581c7483cb8fda268b1214380
Autor:
Surekha Yadav, Sarasa T. Kim, Abuzar Moradi Tuchayi, Fei Jiang, Amanda Morley, Rachelle Saelee, Yingbing Wang, Roxanna Juarez, Courtney Lawnh-Heath, Vadim S. Koshkin, Thomas A. Hope
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Purpose68Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for 177Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with 68Ga-
Externí odkaz:
https://doaj.org/article/eb08e626d53d4b5ba812584ec5be6b29